Cullinan Oncology, Inc. (CGEM) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CGEM Hot Sheet
Join SI Premium – FREE
Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q2 EPS of ($0.75), $0.02 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $0.
For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Texas Capital Securities Downgrades Full House Resorts (FLL) to Hold
- Franklin BSP Realty Trust (FBRT) PT Lowered to $10 at B.Riley
- Enterprise Products Partners (EPD) PT Raised to $39 at Goldman Sachs
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
